RxDoctor Payments Data

Daniel Cassis, MD

Cardiovascular Disease · Miami Beach, FLNPI 1609874940

Payments from drug & device makers

$1,150in general payments, 2019–2025

Across 50 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$825
  • Novo Nordisk$238
  • E.r. Squibb & Sons, L.L.C.$22
  • Amgen$22
  • Alfasigma USA, Inc.$22
  • Johnson & Johnson$20

What the payments were for

  • Food & beverage$1,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis39$825
Novo Nordisk7$238
E.r. Squibb & Sons, L.L.C.1$22
Amgen1$22
Alfasigma USA, Inc.1$22
Johnson & Johnson1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,150 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$254,870
Medicare patients
142
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$79,833
EliquisApixaban76$66,394
Repatha SureclickEvolocumab56$57,058
XareltoRivaroxaban30$45,361
MounjaroTirzepatide16$16,706
Praluent PenAlirocumab17$15,942
JardianceEmpagliflozin15$15,931
Rosuvastatin Calcium386$7,131
Lagevrio (Eua)Molnupiravir12$6,989
Dofetilide35$4,570
Olmesartan Medoxomil137$3,571
VascepaIcosapent Ethyl12$3,531
SymbicortBudesonide/Formoterol Fumarate11$2,509
Nadolol78$2,197
Icosapent Ethyl11$2,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$238$79,83377 claims
Johnson & JohnsonXarelto$20$45,36130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →